- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ocular Therapeutix Inc.
Headquarters: Bedford, MA, United States
Website: http://www.ocutx.com
Year Founded: 2006
Status: Public
Industry Sector: HealthTechnology
CEO: Pravin U. Dugel, MD
Number Of Employees: 274
Enterprise Value: $1,035,265,483
PE Ratio: -6.03
Exchange/Ticker 1: NASDAQ:OCUL
Exchange/Ticker 2: N/A
Latest Market Cap: $1,103,948,928
BioCentury | Sep 4, 2024
Management Tracks
Evers leaving Evotec as CBO
Plus: C-suite changes at Dyne, and updates from Novocure, Amphista, reMYND, Belite Bio, Forward and more
BioCentury | Feb 24, 2024
Finance
Public equity report: Iovance, Ocular Therapeutix cash in on catalysts
In an otherwise slow week for public financings
BioCentury | Feb 23, 2024
Management Tracks
New chair, management changes at Ocular
Plus: Jason Gammack named CEO of Ansa, and updates from LenioBio, Prothena and Ikena
BioCentury | Feb 14, 2023
Finance
Feb. 13 Quick Takes: Hexagon raises $77M for small molecules based on microbial metabolites
Plus: Treeline takes rights to Hengrui’s EZH2 and updates from Cerevance, G1, Frequency, Ocular, Biocon and more
BioCentury | Jan 19, 2023
Management Tracks
Janssen’s Linda Wu to head development at Jiangsu Yahong
Plus: new CEO at Atriva, and updates from Hinge Bio, Capsida, Sensorium, CXL and Patient Square
BioCentury | Jun 9, 2022
Management Tracks
Goldstein becomes president and CMO at Aurion
Plus Duke to be CFO at Apexigen and updates from MC2, Pillar, Nonagen and more
BioCentury | Oct 23, 2021
Product Development
Oct. 22 Quick Takes: FDA approves Genentech’s ocular implant for wet AMD
$118M IPO values Xilio at $427M, plus Genentech, Merck, Sanofi and more
BioCentury | Sep 28, 2021
Management Tracks
New hires at Brii, Ono and PharmaEssentia to strengthen U.S. leadership
Plus: Ocular, Genprex, SAB and more
BioCentury | Mar 31, 2021
Emerging Company Profile
Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline
Emerging Company Profile: $170M raise led by Lake Bleu gives Ji Li cash to hunt neurology, eye disorder assets
BioCentury | Feb 13, 2021
Management Tracks
New venture partners at SR One; plus moves at Surface Oncology, Agenus, AbCellera, BioDelivery, Transcenta, Dewpoint, Cortexyme, Cerevance and Penrose
SR One named Chris Chai and Peter Van Vlasselaer venture partners. Chai was CFO of Principia Biopharma Inc., which Sanofi (Euronext:SAN; NASDAQ:SNY) acquired last year for $3.4 billion. Van
Items per page:
1 - 10 of 80